SEOUL-SEMICONDUCTOR
13.9.2018 15:02:06 CEST | Business Wire | Press release
Seoul Semiconductor (KOSDAQ:046890), a leading global innovator of LED products and technology, has announced that the International Crimes 4 Team at the Gyeonggi Nambu Provincial Police Agency in Korea is expected to detain three individuals, “A” – a former Managing Director of Seoul Semiconductor, “B” and “C” – former employees of Seoul Semiconductor, who divulged automotive LED technology that cost KRW 560 billion and seven years in development to Everlight Electronics, a competitor of Seoul Semiconductor located in Taiwan.
The three individuals will be charged for violating the Act on Prevention of Divulgence and Protection of Industrial Technology, and the Unfair Competition Prevention and Trade Secret Protection Act, and forwarded for prosecution.
Moreover, the CEO of Everlight Electronics and Everlight itself, both liable for the technology divulgence, have been charged under the Act on Prevention of Divulgence and Protection of Industrial Technology.
A, a former Managing Director of Seoul Semiconductor, took umbrage during his salary negotiations and sought out new employment opportunities using technology illegally obtained from Seoul Semiconductor as leverage. During the course of his search, A agreed to join Everlight Electronics in Taiwan as a high-paid Vice President.
Furthermore, investigations revealed that A attempted to use the information he gleaned illicitly from Seoul Semiconductor to develop an LED product for automotive headlights. To expedite development, A offered B and C, both researcher and former subordinate of A at Seoul Semiconductor, salary increases of 200% each and new jobs at Everlight Electronics in return for technical data from Seoul Semiconductor.
B and C took out laptops from the company to show secret materials of Seoul Semiconductor to A, and browsed for the secret information using their laptops at home on weekends to avoid suspicion from their colleagues. B and C also took photos of the information and either sent them via SNS or delivered them in person at Everlight Electronics in Taiwan.
In particular, B and C learned that Seoul Semiconductor had filed an injunction lawsuit against A for prohibition of competitive transaction as he joined Everlight Electronics in Taiwan, and used aliases and fake business cards to avoid litigation. They even denied the fact they were under the employ of Everlight Electronics during the investigation.
However, facts of the case showed that B and C were offered twice their previous salaries at Seoul Semiconductor, residence fee, monthly a week-long holidays, and round-trip airfares, etc. from Everlight Electronics.
Seoul Semiconductor invests approximately 10% of its annual sales into development of LED technology. In 2011, it produced automotive LED the first in Korea. As a result of its endeavors, Seoul Semiconductor holds more than 12,000 patents, and has been listed as one of the top companies around the world in terms of Patent Power compiled by IEEE (Institute of Electrical and Electronics Engineers), a global technical professional organization for electronics and electrical based in the USA. Seoul Semiconductor is the fourth largest LED manufacturer globally. The global LED lighting market currently stands at KRW 37 trillion. However forecasts expect the sector to reach KRW 52 trillion moving forward.
Separate from this case, Seoul Semiconductor has filed lawsuits against Everlight Electronics in Taiwan for five LED patent infringements.
“We estimate that, if A, B, and C were not discovered and charged, it would have lost KRW 560 billion in research and development over a seven-year period, and encroached upon its sales which currently stands at KRW 1 trillion per year,” said Yong Tae Lee, compliance department executive vice president of Seoul Semiconductor.
“The Police will leverage all legal procedures to track down suspects who leak and divulge technology overseas, as in this case, even when said suspects flee the country. Also, it will cooperate with relevant authorities to enforce measures that will allow the Police to restrict imports/exports and prohibit entry of personnel from foreign corporations that engage in industrial espionage. Moreover, it will continue to work on recovering financial damages caused by the divulgence of technology,” said the Gyeonggi Nambu Provincial Police Agency.
|
Lawsuits for LED patent infringements against Everlight Electronics (“E”) |
||||||
| # | Case | Date & News Release | ||||
| 1 |
SSC v. E
|
May 2017 | ||||
| 2 | Feb. 2018 | |||||
| 3 | Feb. 2018 | |||||
| 4 | Jul. 2018 | |||||
| 5 |
Nichia v. E
|
Mar. 2016 |
In China, Nichia filed a patent infringement lawsuit against Everlight’s China subsidiary |
|||
| 6 | Oct. 2016 |
The Japan court rules that distributors of Everlight products infringed Nichia’s patent |
||||
| 7 | Nov. 2016 | |||||
| 8 | May 2017 |
U.S. Federal Court affirms that Everlight infringed Nichia’s patent |
||||
| 9 | Jul. 2017 |
The German court rules that Everlight’s German subsidiary infringed Nichia’s patent |
||||
| 10 |
Bridgelux v. E
|
Aug. 2017 |
In U.S., Bridgelux files a patent Litigation against Everlight for infringement of 5 patents |
|||
* As a result of a lawsuit regarding the prohibition on the change of employment, which forbids a person from joining a competitor of his/her former employer for a set period of time (1~2 years) after termination, defendant A was ordered to pay KRW 100 million for violating his Non-competition agreement and joining Everlight Electronics, and a further KRW 2 million per day if A continues employment at Everlight Electronics. (Seoul Central District Court, April 2017).
About Seoul Semiconductor
Seoul Semiconductor develops and
commercializes light emitting diodes (LEDs) for automotive, general
illumination, specialty lighting, and backlighting markets. As the
fourth-largest LED manufacturer globally, Seoul Semiconductor holds more
than 12,000 patents, offers a wide range of technologies, and mass
produces innovative LED products such as SunLike – delivering the
world’s best light quality in a next-generation LED enabling
human-centric lighting optimized for circadian rhythms; WICOP – a
simpler structured package-free LED which provides market leading color
uniformity and cost savings at the fixture level, providing high lumen
density and design flexibility; NanoDriver Series – the world’s smallest
24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED
technology developed in 2005, including all AC LED-related technologies
from chip to module and circuit fabrication, as well as multi-junction
technology (MJT); and nPola, a new LED product based on GaN-substrate
technology that achieves more than ten times the output of conventional
LEDs. UCD constitutes a high color gamut display which delivers more
than 90% NTSC. To learn more, visit www.seoulsemicon.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005429/en/
Contact:
Seoul Semiconductor Inc. Jeonghee Kim, +82-70-4391-8311 jeonghee.kim@seoulsemicon.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
